Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
Site Search
Showing 1 - 4 of 4 results
News
|
|
3 min read
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
News
|
|
4 min read
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
News
|
|
3 min read
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
News
|
|
3 min read